Ontuxizumab

• CAT Number: I041557
• CAS Number: 946415-62-9
• Purity: ≥95%

Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1].
Ontuxizumab (0-100 μg/mL; 12 h) induces CD248 internalization and dose-dependently reduces 46% CD248 of cell surface of human pericytes[1].
Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice[1].

Reference

[1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40.
 [Content Brief]